Skip to main content
. 2021 Aug;32(8):1974–1986. doi: 10.1681/ASN.2021020231

Figure 3.

Figure 3.

REST protects against podocyte apoptosis. (A) Western blot of REST, cleaved PARP, and γH2AX in HEK cells transfected with REST cDNA plasmid (pREST) or with empty vector (pEV), and treated with 0 or 1 μM of doxorubicin. (B) Immunofluorescence (left) and quantification (right) of cleaved caspase-3 (CC3) in pREST and pEV HEK cells exposed to either 0 or 1 μM of doxorubicin (n=3 experiments). Scale bar, 5 μm. (C) Western blot (left) and quantification (right) of REST, cleaved PARP, and CC3 in pREST or pEV transfected immortalized mouse podocytes exposed to either to 0 or 1 μM of doxorubicin (n=3 experiments). (D) Western blot and quantification of REST, cleaved PARP, and CC3 in HEK transfected cells with siREST or siCtrl and treated with 0 or 1 μM of doxorubicin (n=4 experiments). (E) Western blot (left) and quantifications (right) of REST, cleaved PARP, and CC3 in immortalized mouse podocyte transfected with siREST or siCtrl and treated with 0 or 1 μM of doxorubicin (n=4–6 experiments). All data are shown as the mean±SEM. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 between groups, Mann–Whitney or t test.